Climb Bio, Inc.
Climb Bio, Inc. (CLYM) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CLYM · as of Jun 9, 2026
Key Statistics
Explore Climb Bio, Inc. Data
clym stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 100.0%
The CLYM analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $21.88, representing +103.16% upside from the current price of $10.77.
Competitors & Peers
clym competitorsCLYM
ABOS
ACTU
AGEN
ANIX
ENTXStock Performance
Full HistoryAbout Climb Bio, Inc.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an an…
what is climb bio, inc. · clym stock overview · climb bio, inc. company profile · who is climb bio, inc. ceo · clym NASDAQ · climb bio, inc. headquarters · climb bio, inc. business segments
About Stock Overview & Key Data
Climb Bio, Inc. (CLYM) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 10, 2021. As of the latest trading session, CLYM stock price is $10.77, with a market capitalization of $734.3M. The stock has returned +703.73% over the past 12 months and +169.25% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Climb Bio, Inc. stock is Buy, with an average 12-month price target of $21.88. In fiscal year 2025, Climb Bio, Inc. reported revenue of — and net income of -$59.9M. For detailed data — including Climb Bio, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Climb Bio, Inc. (CLYM) stock price is $10.77. The stock is traded on NASDAQ under the ticker symbol CLYM. The 52-week range is $1.16 – $12.48.